STEMI

基本解释

Method: 70 ACS(STEMI, NSTEMI, UAP) patients and 20 SAPpatients were selected.
方法：选择ACS患者70例，其中ST段抬高的急性心肌梗死(STEMI)患者32例，非ST段抬高的急性心肌梗死(NSTEMI)患者及不稳定型心绞痛(UAP)患者分别为18、20例。
Tirofiban can improve the situation of myocardial reperfusion after PCI in patients with STEMI.
盐酸替罗非班能明显改善STEMI患者急诊PCI后心肌组织的再灌注水平。
Conclusion:Tirofiban can improve the situation of myocardial reperfusion after PCI in patients with STEMI.
结论:盐酸替罗非班能明显改善STEMI患者急诊PCI后心肌组织的再灌注水平。
Out of 373 patients with STEMI referred for primary PCI, 89 patients were presented with MACE during the period of follow-up( average incidence: 23. 9% ).
373例STEMI患者随访期总心血管事件发生89例(平均发生率23.;9%25);
Conclusion: Evaluation of hs-C-reactive protein on admission in STEMI patients undergoing primary PCI allows reliable risk stratification of these patients.
结论：接受直接PCI的STEMI患者入院时检测超敏C反应蛋白水平能够为区分高危患者提供证据。